SCHEMBL22313751

SCHEMBL22313751

CCC(C)c1ccc(-c2ccnc(OC)c2)cc1O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 7/20 0.43
TSHR P16473 1/20 0.41
CYP3A4 P08684 1/20 0.41
SLC13A5 Q86YT5 1/20 0.40
LOX P28300 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
CHRNA7 P36544 1/20 0.37
CNR1 P21554 1/20 0.36
CYP17A1 P05093 1/20 0.36
S1PR1 P21453 1/20 0.36
RORC P51449 1/20 0.36
SRC P12931 1/20 0.35
FEN1 P39748 1/20 0.35
LIPC P11150 1/20 0.35
LIPG Q9Y5X9 1/20 0.35
LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22214071 0.86 TRPA1 (0.46) AAK1CYP3A4SLC13A5LOXLOXL2
SCHEMBL22313025 0.83 GABRG2 (0.45) TSHRCYP17A1RORCSRC
SCHEMBL22313720 0.82 TSHR (0.40) TSHRRORCSRC
SCHEMBL22313787 0.77 SLC13A5 (0.45) AAK1CYP3A4SLC13A5LOXLOXL2
SCHEMBL22797385 0.75 S1PR1 (0.49) AAK1SLC13A5LOXLOXL2CHRNA7
SCHEMBL16116782 0.73 LOX (0.55) AAK1SLC13A5LOXLOXL2CHRNA7
SCHEMBL30626327 0.73 LOX (0.55) AAK1SLC13A5LOXLOXL2CHRNA7
SCHEMBL22283952 0.73 HSD17B1 (0.49) AAK1SLC13A5LOXLOXL2CHRNA7
SCHEMBL22214083 0.72 TSHR (0.44) AAK1TSHRRORCLRRK2
SCHEMBL11961096 0.71 TYR (0.59) TSHRCYP3A4RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-11162101-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-11-02 US disclosed
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 AAK1 1970/4885TSHR 4288/4885CYP3A4 4486/4885
US-11162101-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 AAK1 1970/4885TSHR 4288/4885CYP3A4 4486/4885
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 AAK1 1970/4885TSHR 4288/4885CYP3A4 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.